Bioxytran, Inc. has reported its financial results for the third quarter and nine months ended September 30, 2025, revealing a net loss of $282,726 for the quarter and $1,600,922 for the nine-month period. This represents a decrease in losses compared to the same periods in 2024, where the company reported losses of $392,374 and $1,614,543, respectively. The company has not generated any revenue from operations, as its products remain in the research and development phase. As of September 30, 2025, Bioxytran's accumulated deficit stood at $20,522,092, up from $18,921,169 at the end of 2024.
In terms of financial position, Bioxytran's total assets increased to $156,294 as of September 30, 2025, compared to $138,694 at the end of 2024. Current liabilities surged to $3,060,937, up from $1,930,642, primarily due to increased accounts payable and accrued expenses, which rose to $823,453 from $271,308. The company also reported a significant increase in loans from affiliates, which amounted to $541,405, compared to $241,078 at the end of the previous year. The company's cash position improved slightly, ending the quarter with $14,499, up from $5,154 at the end of 2024.
Operationally, Bioxytran has made strategic moves, including the acquisition of Pharmalectin, Inc. and NDPD Pharma, Inc., which are focused on developing therapeutic drugs and specialized pharmaceutical manufacturing equipment, respectively. The company has also been active in clinical trials, with ongoing studies for its ProLectin-M product aimed at treating COVID-19 and other related conditions. The recruitment for a Phase 1b/2a trial was completed in May 2025, with results expected to be published soon.
Despite these developments, the company faces significant challenges, including a negative working capital of $3,046,438 and the need to raise at least $3,700,000 to sustain operations over the next 15 months. Bioxytran has indicated that it is pursuing additional capital through private placements and public offerings but acknowledges the difficulty of raising funds in a depressed market. The company has also noted that its current cash reserves will not be sufficient to meet operational needs beyond November 2025.
Looking ahead, Bioxytran's management remains focused on securing funding to support its ongoing research and development efforts. The company plans to continue its clinical trials and aims to advance its product pipeline, particularly the BXT-25 molecule designed for stroke treatment. However, the ability to execute these plans is contingent upon obtaining the necessary financial resources, and the company has expressed uncertainty regarding its future viability without additional capital.
About BIOXYTRAN, INC
Bioxytran, Inc. is a clinical-stage pharmaceutical company developing therapeutic drugs targeting hypoxia, a condition of oxygen deficiency in tissues. Its lead candidate, BXT-25, is a novel oxygen-carrying small molecule designed to treat stroke-related brain hypoxia. Through its subsidiary Pharmalectin, the company develops galectin antagonist-based therapies for viral diseases, including COVID-19. Bioxytran focuses on innovative co-polymer chemistry, leveraging proprietary technology to address unmet medical needs via licensing partnerships.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.